Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study

BACKGROUND: In this open‐label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) who had a confirmed T790M mutation and disease progression on previous epidermal growth factor rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Jӓnne, Pasi A., Kim, Dong‐Wan, Han, Ji‐Youn, Wu, Ming‐Fang, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Lee, Dae Ho, Cho, Byoung Chul, Yu, Chong‐Jen, Pang, Yong Kek, Felip, Enriqueta, Kim, Hyunjin, Baek, Eunhye, Noh, Young Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247868/
https://www.ncbi.nlm.nih.gov/pubmed/33434335
http://dx.doi.org/10.1002/cncr.33385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247868/
https://www.ncbi.nlm.nih.gov/pubmed/33434335
http://dx.doi.org/10.1002/cncr.33385

Ejemplares similares